Literature DB >> 1094819

Comparative hemodynamic effects of placebo and oral isosorbide dinitrate in patients with significant coronary artery disease.

H Kasparian, L Wiener, P R Duca, R S Gottlieb, A N Brest.   

Abstract

Comparative hemodynamic effects of placebo and 10 mg of oral isosorbide dinitrate were studied in patients with significant coronary artery disease (larger than or equal to 75 per cent lumen narrowing) proved angiographically. Isosorbide dinitrate or placebo was given to eight and 10 patients, respectively, in a double-blind fashion. Cardiac performance at rest and during supine leg exercise was evaluated before and 60 minutes after drug administration. In the resting state, isosorbide dinitrate compared to placebo significantly reduced the left ventricualr (systolic and diastolic), mean pulmonary artery and mean aortic pressures, cardiac index, stroke index, left ventricular work index, stroke work index, and mean systolic ejection rate. Isosorbide dinitrate also significantly reduced left ventricular (systolic and diastolic and mean pulmonary artery pressures during exercise. This study indicates that 10 mg of isosorbide dinitrate has a significant influence on ischemic left ventricular dysfunction 60 minutes after its oral administration.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1094819     DOI: 10.1016/0002-8703(75)90258-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  3 in total

1.  Increased exercise tolerance with nitrates in beta-blockaded patients with angina.

Authors:  R H Baxter; I M Lennox
Journal:  Br Med J       Date:  1977-08-27

2.  Comparative haemodynamic and peripheral vasodilator effects of oral and chewable isosorbide dinitrate in patients with refractory congestive cardiac failure.

Authors:  J Figueras; W R Taylor; T Ogawa; J S Forrester; B N Singh; H J Swan
Journal:  Br Heart J       Date:  1979-03

3.  Haemodynamics and plasma concentrations following sublingual GTN and intravenous, or inhaled, isosorbide dinitrate.

Authors:  W Culling; H Singh; A Bashir; B E Griffiths; J J Dalal; D J Sheridan
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.